ATE.v/ATBPF +.075 to C$.355 Big volume 5.22million shares traded this morning. Price target was C$.85 IF ATB-346 was approved but that's not likely before 2020 and commercialization in 2021 if everything goes smoothly. It helps that naproxen has already been out in the marketplace for many years. This is naproxen with the addition of a hydrogen sulfide compound to minimize GI tract damage.
Market Data 
Markets 
AI
